LP 128
Alternative Names: LP-128; NWP-1080Latest Information Update: 05 Jan 2022
At a glance
- Originator Newave Pharmaceuticals
- Developer Guangzhou Lupeng Pharmaceutical
- Class Antivirals; Heterocyclic compounds; Small molecules
- Mechanism of Action Hepatitis B surface antigen expression inhibitors; Hepatitis B virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hepatitis B